Otsuka’s SIMTRIYO has FDA approval, but two hurdles will decide whether it can disrupt ADHD care
Otsuka’s SIMTRIYO wins FDA approval for ADHD, but DEA scheduling, boxed warnings and payer access will shape its commercial uptake.
Pharma & Biotech
Pharma & Biotech
Otsuka reports VOYXACT preserved kidney function for two years in Phase 3 trial
Otsuka’s two-year VOYXACT data could reshape IgA nephropathy care. See what the eGFR results mean for FDA approval and clinical adoption.